Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

cyclosporine

CYCLOSPORINE

cyclosporine (CYCLOSPORINE) is a cyclophilin a modulator. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved NMPA: clinical trials
US status approved
Patents linked 18
Pipeline programs 14
News articles 0
Drug details — cyclosporine
US status
approved
Class
—
Route
OPHTHALMIC
Patents
18
Programs
14
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

cyclosporine (CYCLOSPORINE) is a cyclophilin a modulator. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN cyclosporine
Brand CYCLOSPORINE
Mechanism Cyclophilin A modulator
Target Peptidyl-prolyl cis-trans isomerase A
Route OPHTHALMIC
Formulation EMULSION
Originator Amneal Pharma Europe Ltd

Mechanism of action

Cyclophilin A modulator

Primary target: Peptidyl-prolyl cis-trans isomerase A

Approval history

Authority Status Date
FDA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline Sponsor programs
  1. cyclosporine Phase 3 · Shanghai Medical College · Graft Versus Host Disease
  2. cyclosporine Phase 3 · Takeda · Leukemia
  3. Cyclosporine A Phase 2 · First People's Hospital · Bone Marrow Failure Disorders
  4. IIT2014006 Phase 2 · Chinese Academy of · Aplastic Anemia
  5. cyclosporine Phase 2 · Ultragenyx UK · Sickle Cell Anemia
  6. cyclosporine (reduced exposure) / everolimus Phase 2 · Novartis India · Kidney Transplantation
  7. AT-527 550 mg + cyclosporine Phase 1 · Atea Pharmaceuticals · Healthy Volunteer Study
  8. C3421063 Phase 1 · First Biotech (Australia) · Type 2 Diabetes Mellitus, Obesity, Overweight management

Related & competitor drugs

Browse all drugs
  1. ciclosporin Sensory organs (S01)

Related patents

Browse patents Amneal Pharma Europe Ltd patent hub

  1. US 12409206

    Use of cyclosporine analogues for treating fibrosis

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12226429

    Highly active compounds against COVID-19

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11813278

    Highly active compounds against COVID-19

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11738038

    Highly active compounds against COVID-19

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11707480

    Highly active compounds against COVID-19

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10888529

    Vehicles for the transfection of miRNAs

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10874687

    Highly active compounds against COVID-19

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10610597

    Polycarbonates bearing aromatic N-heterocycles for drug delivery

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10472394

    Cyclosporine analogue mixtures and their use as immunomodulating agents

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9919027

    Lipid nanoparticle of polymyxin

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9765119

    Cyclosporine analogue mixtures and their use as immunomodulating agents

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9717797

    Polycarbonates bearing aromatic N-heterocycles for drug delivery

    Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7521421

    Deuterated cyclosporine analogs and methods of making the same

    Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7332472

    Cyclosporine analogue mixtures and their use as immunomodulating agents

    Expires Mon Feb 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 6998385

    Cyclosporine analogue mixtures and their use as immunomodulating agents

    Expires Mon Feb 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  16. US 6686454

    Antibodies to specific regions of cyclosporine related compounds

    Expires Mon Jan 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  17. US 6613739

    Deuterated cyclosporine analogs and their use as immunomodulating agents

    Expires Mon Aug 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  18. US 6605593

    Deuterated cyclosporine analogs and their use as immunomodulating agents

    Expires Mon Aug 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is cyclosporine?

cyclosporine (CYCLOSPORINE) is a cyclophilin a modulator. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for cyclosporine?

CYCLOSPORINE is a marketed brand name for cyclosporine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cyclosporine?

cyclosporine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.